BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163 - Yahoo Finance
BioNTech SE First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech's infectious disease mRNA vaccine collaboration with the University of Pennsylvania to enter the clinic The program is part of BioNTech's strategy to address diseases with high unmet medical need, as no vaccine has been approved for prevention of genital lesions caused by HSV MAINZ, Germany, December 21, 2022 – BioNTech SE (Nasdaq: BNTX, "BioNTech" or the "Company") today announced that the first subject was dosed in a first-in-human Phase 1 clinical research study with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1. The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163. The mRNA vaccine encodes three HSV-2 glycoproteins with the aim of helping to prevent HSV...